跳至主要内容
临床试验/NCT05211193
NCT05211193已完成不适用

Open Label, Multi Center Study to Evaluate the Efficacy of the Home Based Electrical Transcutaneous NeuroModulation (eTNM) Treatment Via Nerve Stimulator URIS I (Tesla Medical) in the Treatment of Overactive Bladder (OAB).

Stimvia s.r.o.1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2020年1月8日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
40
试验地点
1
主要终点
Change of severe urgency episodes

研究概览

简要总结

Open label Study to Evaluate the Efficacy of the Home Based Electrical Transcutaneous NeuroModulation (eTNM) Treatment Via Nerve Stimulator URIS I in the Treatment of Overactive Bladder.

详细描述

Open label, Multi center Study to Evaluate the Efficacy of the Home Based Electrical Transcutaneous NeuroModulation (eTNM) Treatment Via Nerve Stimulator URIS I in the Treatment of Overactive Bladder (OAB).

研究设计

研究类型
Observational
观察模型
Other
时间视角
Other

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Women 18 years or older, inclusive
  • Diagnosis of OAB or mixed incontinence with the predominance of OAB symptoms
  • Dissatisfaction with any current or previous pharmacotherapy treatment of OAB for any reason within the past 12 months
  • Treatment Satisfaction VAS <50
  • Ability to understand and sign ICF
  • Subject agreed to attend all follow up evaluations and was willing to completely and accurately fill out voiding diaries and questionnaires, and was willing to complete required exams and tests
  • Subject agreed not to participate in another research study from the time of screening until the final study visit
  • Subject agreed not to use a pharmacotherapy treatment for OAB from the time of screening until the final study visit

排除标准

  • Prior treatment with botulotoxin for OAB
  • Previous pharmacotherapy for OAB if >12 months ago
  • Urinary retention with post void residual > 150ml
  • Neurological disease affecting urinary bladder function, including but not limited to Parkinson's disease, multiple sclerosis, stroke, spinal cord injury and nerves of lower limbs
  • History or presence of stress incontinence, or mixed incontinence where stress incontinence was predominant

结局指标

主要结局

Change of severe urgency episodes

时间窗: baseline and end of study (6weeks treatment)

The proportion of subjects with ≥ 50% change in severe urgency episodes (Grade 3 or 4) will be summarized by visit and for the full treatment period using the last observation.

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Open Label Study to Evaluate the Efficacy of the... | 临床试验